B. Riley Has Lowered Expectations for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) had its target price decreased by B. Riley from $4.00 to $3.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. B. Riley also issued estimates for Lineage Cell Therapeutics' Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

Several other brokerages have also commented on LCTX. Maxim Group decreased their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lineage Cell Therapeutics currently has an average rating of "Buy" and an average target price of $4.20.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX traded down $0.02 on Friday, reaching $0.48. 2,410,294 shares of the stock traded hands, compared to its average volume of 1,239,593. The firm has a market cap of $106.18 million, a price-to-earnings ratio of -4.01 and a beta of 1.21. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61. The stock's 50-day moving average is $0.60.

Remove Ads

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Defender Capital LLC. boosted its stake in Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company's stock worth $2,997,000 after purchasing an additional 961,150 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Lineage Cell Therapeutics by 2.3% during the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company's stock valued at $3,331,000 after acquiring an additional 83,274 shares during the period. Barclays PLC lifted its stake in shares of Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company's stock valued at $192,000 after acquiring an additional 159,924 shares during the period. State Street Corp lifted its stake in shares of Lineage Cell Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,608,352 shares of the company's stock valued at $2,361,000 after acquiring an additional 45,483 shares during the period. Finally, Atria Wealth Solutions Inc. acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter valued at $29,000. Institutional investors and hedge funds own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.